Neurodegenerative Clinical Outcomes | Achieving GCT Success
Friday, May 21, 2021
10:10 AM – 10:35 AM
Hot Topics
Can stem cell-based platforms become successful treatments for neurodegenerative diseases?
- What are the commonalities driving GCT success in neurodegenerative disease and non-neurologic disease, what are the key differences?
- Overcoming treatment administration challenges
- GCT impact on degenerative stage of disease
- How difficult will it be to titrate the size of the cell therapy effect in different neurological disorders and for different patients?
- Demonstrating clinical value to patients and payers
- Revised clinical trial models to address issues and concerns specific to GCT
- Moderator:
-
- Bob Carter, MD, PhD
-
- Chairman, Department of Neurosurgery, MGH
- William and Elizabeth Sweet, Professor of Neurosurgery, HMS
- Speakers:
-
- Erwan Bezard, PhD
-
- INSERM Research Director, Institute of Neurodegenerative Diseases
- Nikola Kojic, PhD
-
- CEO and Co-Founder, Oryon Cell Therapies
- Geoff MacKay
-
- President & CEO, AVROBIO
- Viviane Tabar, MD
-
- Founding Investigator, BlueRock Therapeutics
- Chair of Neurosurgery, Memorial Sloan Kettering
-
Q&A
10:40 AM – 10:55 AM